Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02211261 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus
A Phase 1 study of Type 2 Diabetes Mellitus, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
- 7
- Study locations
NCT02211261: Completed Phase 1 study of Type 2 Diabetes Mellitus, sponsored by Pfizer.
NCT02211261 is a Phase 1 study of Type 2 Diabetes Mellitus that has completed, run by Pfizer. The registered enrollment target is 84 participants, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (97% lower). The trial reports 7 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02211261, a Phase 1 study of Type 2 Diabetes Mellitus, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
- 7
- Study locations
Study Summary
A first in human study to determine the safety, tolerability and pharmacokinetics of single and multiple ascending doses of PF-06293620 in subjects with Type 2 Diabetes Mellitus
Primary Outcome
An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of its causal relationship with study treatment. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; was life-threatening (immediate risk of death); persistent or significant disability/incapacity; congenital anomaly. Tre
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL PF-06293620
Study Locations (7)
Florida
- Avail Clinical Research, LLC - DeLand
- Orlando Clinical Research Center - Orlando
- Qps Mra, Llc - South Miami
- Qps-Mra Llc - South Miami
California
- Profil Institute for Clinical Research, Inc. - Chula Vista
- Profil Institute for Clinical Research, Incorporated - Chula Vista
North Carolina
- High Point Clinical Trials Center, LLC - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2014-09-15 |
| Est. Completion | 2017-01-27 |
| Phase | Phase 1 |
What the finished NCT02211261 record still lists
NCT02211261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 2,959-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02211261 lists 7 locations in 3 states (Florida, California, North Carolina).
Frequently Asked Questions
What is clinical trial NCT02211261 about?
NCT02211261 is a clinical study titled "A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus". A first in human study to determine the safety, tolerability and pharmacokinetics of single and multiple ascending doses of PF-06293620 in subjects with Type 2 Diabetes Mellitus
What is the current status of trial NCT02211261?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2014-09-15. Estimated completion is 2017-01-27.
What conditions does trial NCT02211261 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT02211261?
The interventions under investigation include: Placebo (BIOLOGICAL), PF-06293620 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02211261?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02211261 being conducted?
This trial has 7 study locations across California, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02211261's enrollment target sits among peer trials
84 62nd of 130 higher than 69 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
Single Cohort, 2-Period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine 500 mg
COMPLETED · Phase 1
-
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
COMPLETED · Phase 1
-
A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol
COMPLETED · Phase 1
-
Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI